Multi-product ophthalmic commercial roll-up with $350M+ revenue guidance bets on MELT-300 NDA to add a non-ophthalmic growth leg

Bull

A successful NDA submission incorporating clean pharmacokinetic and non-clinical data positions MELT-300 for FDA review and potential approval, opening a procedural sedation market that is entirely outside Harrow's current ophthalmic revenue base. Approval would validate the Melt Pharmaceuticals acquisition, allow Harrow to retire the lower-margin compounded MKO Melt product, and provide an additional revenue stream that reduces concentration risk in the ophthalmic portfolio — directly de-risking the $350M+ revenue guidance that currently depends heavily on VEVYE and the newly launched biosimilars.

Bear

The most likely failure modes are deficiencies in the ancillary studies — pharmacokinetic data that fails to characterize the drug's sedation profile adequately, or non-clinical findings that introduce a safety signal — either of which could trigger a refuse-to-file or complete response letter rather than an approval pathway. Additionally, because procedural sedation requires demonstration of a well-controlled depth of sedation with an acceptable therapeutic window, any ambiguity in the efficacy or safety boundary could lead the FDA to require additional clinical work, substantially delaying the commercial launch and leaving the thesis's diversification argument unfulfilled.